Latest news with #NasdaqCapitalMarket
Yahoo
4 days ago
- Business
- Yahoo
Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 15, 2025
NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of July 15, 2025, short interest in 3,260 Nasdaq Global MarketSM securities totaled 13,792,841,090 shares compared with 14,138,758,851 shares in 3,257 Global Market issues reported for the prior settlement date of June 30, 2025. The mid-July short interest represents 2.37 days compared with 2.59 days for the prior reporting period. Short interest in 1,647 securities on The Nasdaq Capital MarketSM totaled 2,853,251,720 shares at the end of the settlement date of July 15, 2025, compared with 2,790,159,938 shares in 1,636 securities for the previous reporting period. This represents a 1.00 day average daily volume; the previous reporting period's figure was 1.00. In summary, short interest in all 4,907 Nasdaq® securities totaled 16,646,092,810 shares at the July 15, 2025 settlement date, compared with 4,893 issues and 16,928,918,789 shares at the end of the previous reporting period. This is 1.84 days average daily volume, compared with an average of 1.72 days for the prior reporting period. The open short interest positions reported for each Nasdaq security reflect the total number of shares sold short by all broker/dealers regardless of their exchange affiliations. A short sale is generally understood to mean the sale of a security that the seller does not own or any sale that is consummated by the delivery of a security borrowed by or for the account of the seller. For more information on Nasdaq Short interest positions, including publication dates, visithttp:// Nasdaq:Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at NDAQO Media Contact: Maximilian A photo accompanying this announcement is available at
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
HERZLIYA, Israel and CALGARY, Alberta, July 23, 2025 /PRNewswire/ — Innocan Pharma Corporation ('Innocan' or the 'Company') (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the 'SEC') relating to a proposed public offering of units (each, a 'Unit' and collectively, the 'Units') in the United States. Each Unit will be comprised of one common share of the Company (a 'Common Share') and one common share purchase warrant of the Company (a 'Warrant'). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price and term in the context of the market. Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols 'INNP' and 'INNPW', respectively. ThinkEquity is acting as sole book-running manager for the offering. This proposed offering will be made only by means of a prospectus. Upon availability, copies of the preliminary prospectus related to the proposed offering may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at A registration statement relating to this offering has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Iris Bincovich Innocan Pharma's CEO stated: 'The entire Innocan Pharma team and I are thrilled with having taken this significant step in the process of our listing on the Nasdaq, which opens up exciting new opportunities for us on multiple levels.' About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. For further information, please contact: Iris Bincovich, CEO15162104025++972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Disclaimer for Forward-Looking Information This press release includes certain statements and information that may constitute 'forward-looking information' within the meaning of applicable Canadian securities laws and/or 'forward-looking statements' within the meaning of applicable United States securities laws (collectively, 'forward-looking statements'). Forward-looking statements relate to future events or future performance and reflect the Company's current estimates, predictions, expectations or beliefs regarding future events and include, without limitation, statements with respect to: statements relating to the public offering of the Company's common shares; the expected timing of the public offering; the registration and listing of the Company's common shares in the United States; the registration statement becoming effective; the SEC's review process; the sizing and pricing of the offering; the means by which the offering will be made; and the Company's business strategies. Often, but not always, forward-looking statements may be identified by the use of words such as 'expects', 'anticipates', 'plans', 'projects', 'estimates', 'assumes', 'intends', 'strategy', 'goals', 'objectives' or variations thereof or stating that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements in this press release are based upon, without limitation, the following estimates and assumptions: the Company carrying out its public offering; the Company successfully completing the SEC review process; obtaining requisite regulatory approvals; and general business, economic and market conditions. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Important factors that may cause actual results to vary, include, without limitation, that the Company may not carry out its public offering or complete the SEC review process. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement or forward-looking information, except in accordance with applicable securities laws. Logo – View original content:
Cision Canada
6 days ago
- Business
- Cision Canada
Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
HERZLIYA, Israel and CALGARY, Alberta, July 23, 2025 /CNW/ -- Innocan Pharma Corporation (" Innocan" or the " Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the " SEC") relating to a proposed public offering of units (each, a " Unit" and collectively, the " Units") in the United States. Each Unit will be comprised of one common share of the Company (a " Common Share") and one common share purchase warrant of the Company (a " Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price and term in the context of the market. Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols "INNP" and "INNPW", respectively. ThinkEquity is acting as sole book-running manager for the offering. This proposed offering will be made only by means of a prospectus. Upon availability, copies of the preliminary prospectus related to the proposed offering may be obtained from ThinkEquity, 17 State Street, 41 st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at A registration statement relating to this offering has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Iris Bincovich Innocan Pharma's CEO stated: "The entire Innocan Pharma team and I are thrilled with having taken this significant step in the process of our listing on the Nasdaq, which opens up exciting new opportunities for us on multiple levels." About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. For further information, please contact: Iris Bincovich, CEO 15162104025+ +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Disclaimer for Forward-Looking Information This press release includes certain statements and information that may constitute "forward-looking information" within the meaning of applicable Canadian securities laws and/or "forward-looking statements" within the meaning of applicable United States securities laws (collectively, "forward-looking statements"). Forward-looking statements relate to future events or future performance and reflect the Company's current estimates, predictions, expectations or beliefs regarding future events and include, without limitation, statements with respect to: statements relating to the public offering of the Company's common shares; the expected timing of the public offering; the registration and listing of the Company's common shares in the United States; the registration statement becoming effective; the SEC's review process; the sizing and pricing of the offering; the means by which the offering will be made; and the Company's business strategies. Often, but not always, forward-looking statements may be identified by the use of words such as "expects", "anticipates", "plans", "projects", "estimates", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements in this press release are based upon, without limitation, the following estimates and assumptions: the Company carrying out its public offering; the Company successfully completing the SEC review process; obtaining requisite regulatory approvals; and general business, economic and market conditions. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Important factors that may cause actual results to vary, include, without limitation, that the Company may not carry out its public offering or complete the SEC review process. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Readers are cautioned that reliance on such information may not be appropriate for other purposes.
Yahoo
6 days ago
- Business
- Yahoo
Bit Digital's (BTBT) WhiteFiber Inc is Getting Ready for an IPO
Bit Digital, Inc. (NASDAQ:BTBT) is one of the . On July 16, Bit Digital, Inc. (NASDAQ:BTBT) announced that its subsidiary, WhiteFiber Inc., submitted a Form S-1 registration statement to the US Securities and Exchange Commission, as it prepares for launching an initial public offering. The size and price range of the offering are still to be determined. The IPO will only proceed after the SEC reviews and approves the registration, and if market conditions are appropriate. A team of technicians working on a server of bitcoin mining equipment in a data center. WhiteFiber aims to list its shares on the Nasdaq Capital Market, with the ticker symbol 'WYFI.' Moreover, B. Riley Securities and Needham & Company will manage the IPO process as joint bookrunners. Bit Digital, Inc. (NASDAQ:BTBT) provides high-performance computing infrastructure and digital asset services. Its subsidiary WhiteFiber offers GPU cloud services and operates HPC data centers that support demanding AI and machine learning workloads. While we acknowledge the potential of BTBT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
18-07-2025
- Business
- Business Insider
Aeries Technology regains compliance with Nasdaq listing requirements
Aeries Technology (AERT) announced that it has restored compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and will continue to trade on the Nasdaq Capital Market. The company stated no hearing or appeal process was necessary, and the matter is now fully closed. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
